7 OVERVIEW

7 Latest key takeaways

9 DISEASE BACKGROUND

9 Definition

9 Patient segmentation

10 Risk factors

11 Symptoms

11 Diagnosis

13 TREATMENT

13 Referral patterns

13 Standard of care by disease progression

13 Preferred systemic therapy regimens for locally advanced disease

16 Preferred systemic therapy regimens for very advanced disease

16 Approved marketed drugs

18 EPIDEMIOLOGY

18 Incidence methodology

22 MARKETED DRUGS

25 PIPELINE DRUGS

40 KEY REGULATORY EVENTS

40 Supplemental Approvals Boost Opdivo And Gardasil 9, But Limit Beovu

40 NICE Draft Guidance: Rejects Keytruda In Head And Neck Cancer

40 EU Approvals: Keytruda Cleared For First-Line Head And Neck Cancer

41 PROBABILITY OF SUCCESS

42 LICENSING AND ASSET ACQUISITION DEALS

42 Regeneron Increases Stake In ISA Pharma, Plans Pivotal Study

42 Junshi, Merck KGaA To Explore Head And Neck Cancer Combo

42 Norgine Expands Portfolio With Azanta Acquisition

42 Tech Transfer Roundup: MD Anderson Inks Set of IO Deals Covering US, UK, Japan, China

43 Idera Pharmaceuticals Inc. and AbbVie Inc. Forged a Trial Collaboration to Study Combinations of ABBV368, Tilsotolimod,
Nab-Paclitaxel, and/or ABBV181

44 CLINICAL TRIAL LANDSCAPE

45 Sponsors by status

46 Sponsors by phase

47 Recent events

49 DRUG ASSESSMENT MODEL

52 MARKET DYNAMICS

53 FUTURE TRENDS

53 Standard of care shifting to immunotherapies

53 Keytruda's dominant position bolstered by label expansions

53 Immunotherapies compete for approval in newly diagnosed HNSCC

54 Growing interest in combination immunotherapies in recurrent/metastatic HNSCC

54 Other novel approaches lag behind checkpoint inhibitors

55 CONSENSUS FORECASTS

57 RECENT EVENTS AND ANALYST OPINION

57 ALX148 for Head and Neck Cancer (May 29, 2020)

58 Imfinzi for Head and Neck Cancer (May 29, 2020)

59 NBTXR3 (Drug) for Head and Neck Cancer (May 29, 2020)

61 Tipifarnib (Oncology) for Head and Neck Cancer (May 29, 2020)

63 Bavencio for Head and Neck Cancer (March 13, 2020)

64 Debio 1143 for Head and Neck Cancer (September 30, 2019)

66 Monalizumab for Head and Neck Cancer (September 30, 2019)

68 ABBV-368 for Head and Neck Cancer (September 4, 2019)

69 Enoblituzumab for Head and Neck Cancer (July 10, 2019)

70 ASP-1929 for Head and Neck Cancer (June 1, 2019)

71 SD-101 (TriSalus) for Head and Neck Cancer (June 1, 2019)

72 Keytruda for Head and Neck Cancer (May 31, 2019)

74 Ibrance for Head and Neck Cancer (May 15, 2019)

76 Imfinzi for Head and Neck Cancer (May 15, 2019)

77 Trodelvy for Head and Neck Cancer (April 29, 2019)

78 Opdivo for Head and Neck Cancer (April 25, 2019)

81 KEY UPCOMING EVENTS

82 KEY OPINION LEADER INSIGHTS

83 BIBLIOGRAPHY

83 Prescription information

84 APPENDIX

LIST OF FIGURES

10 Figure 1: TNM classifications for HNSCCs

20 Figure 2: Trends in incident cases of head and neck cancer, 2018-27

25 Figure 3: Overview of pipeline drugs for head and neck cancer in the US

25 Figure 4: Pipeline drugs for head and neck cancer, by company

26 Figure 5: Pipeline drugs for head and neck cancer, by drug type

26 Figure 6: Pipeline drugs for head and neck cancer, by classification

41 Figure 7: Probability of success in the head and neck cancer pipeline

44 Figure 8: Clinical trials in head and neck cancer

44 Figure 9: Top 10 drugs for clinical trials in head and neck cancer

45 Figure 10: Top 10 companies for clinical trials in head and neck cancer

45 Figure 11: Trial locations in head and neck cancer

46 Figure 12: Head and neck cancer trials status

47 Figure 13: Head and neck cancer trials sponsors, by phase

49 Figure 14: Datamonitor Healthcare's drug assessment summary for head and neck cancer

52 Figure 15: Market dynamics in head and neck cancer

53 Figure 16: Future trends in head and neck cancer

59 Figure 17: Imfinzi for Head and Neck Cancer (May 29, 2020): Phase II - CheckRad-CD8 (w/Tremelimumab)

61 Figure 18: NBTXR3 (Drug) for Head and Neck Cancer (May 29, 2020): Phase I - NBTXR3-1100 (w/Nivolumab or Pembrolizumab)

63 Figure 19: Tipifarnib (Oncology) for Head and Neck Cancer (May 29, 2020): Phase II - RUN-HN (HRAS Mutations)

66 Figure 20: Debio 1143 for Head and Neck Cancer (September 30, 2019): Phase I/II - LA-SCCHN

68 Figure 21: Monalizumab for Head and Neck Cancer (September 30, 2019): Phase Ib/II - w/Cetuximab (US and EU)

71 Figure 22: ASP-1929 for Head and Neck Cancer (June 1, 2019): Phase I/IIa - w/PIT

74 Figure 23: Keytruda for Head and Neck Cancer (May 31, 2019): Phase III - KEYNOTE-048

76 Figure 24: Ibrance for Head and Neck Cancer (May 15, 2019): Phase II - PALATINUS (w/Cetuximab)

77 Figure 25: Imfinzi for Head and Neck Cancer (May 15, 2019): Phase III - EAGLE (+/-Tremelimumab)

80 Figure 26: Opdivo for Head and Neck Cancer (April 25, 2019): Phase II - CheckMate-714

81 Figure 27: Key upcoming events in head and neck cancer

LIST OF TABLES

9 Table 1: Head and neck cancer: ICD-10 diagnosis codes

15 Table 2: Recommended (Category 1) chemotherapy regimens for locally advanced disease, by origin of primary tumor

16 Table 3: Preferred systemic therapy regimens for very advanced disease, by origin of primary tumor

17 Table 4: Approved marketed drugs for head and neck cancer

19 Table 5: Incident cases of head and neck cancer, 2018-27

21 Table 6: Incident cases of head and neck cancer, by gender, 2018

23 Table 7: Marketed drugs for head and neck cancer

27 Table 8: Pipeline drugs for head and neck cancer in the US

55 Table 9: Historical global sales, by drug ($m), 2015-19

55 Table 10: Forecasted global sales, by drug ($m), 2020-24

57 Table 11: ALX148 for Head and Neck Cancer (May 29, 2020)

58 Table 12: Imfinzi for Head and Neck Cancer (May 29, 2020)

60 Table 13: NBTXR3 (Drug) for Head and Neck Cancer (May 29, 2020)

62 Table 14: Tipifarnib (Oncology) for Head and Neck Cancer (May 29, 2020)

64 Table 15: Bavencio for Head and Neck Cancer (March 13, 2020)

65 Table 16: Debio 1143 for Head and Neck Cancer (September 30, 2019)

67 Table 17: Monalizumab for Head and Neck Cancer (September 30, 2019)

68 Table 18: ABBV-368 for Head and Neck Cancer (September 4, 2019)

69 Table 19: Enoblituzumab for Head and Neck Cancer (July 10, 2019)

70 Table 20: ASP-1929 for Head and Neck Cancer (June 1, 2019)

72 Table 21: SD-101 (TriSalus) for Head and Neck Cancer (June 1, 2019)

73 Table 22: Keytruda for Head and Neck Cancer (May 31, 2019)

75 Table 23: Ibrance for Head and Neck Cancer (May 15, 2019)

76 Table 24: Imfinzi for Head and Neck Cancer (May 15, 2019)

78 Table 25: Trodelvy for Head and Neck Cancer (April 29, 2019)
79 Table 26: Opdivo for Head and Neck Cancer (April 25, 2019)